Clear Search

Showing 1 result for “McCasland L”.

November 2022

Efficacy And Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results from the Keepsake 1 Study

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac607

Risankizumab (RZB) improves the signs and symptoms of PsA, with efficacy maintained through 52 weeks. Alongside the efficacy data, this analysis of KEEPsAKE 1 also evaluates the safety and tolerability profile of RZB.

more…